We are live on
!
Find out more
DOFI
DCVC Opportunity Fund II Portfolio holdings
AUM
$13.9M
1-Year Est. Return
8.04%
This Fund
S&P 500
This Quarter
Est. Return
-20.99%
1 Year Est. Return
+8.04%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$200M
AUM Growth
–
Cap. Flow
+$224M
Cap. Flow
% of AUM
112.49%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rocket Lab Corp
RKLB
|
+$99M |
| 2 |
Recursion Pharmaceuticals
RXRX
|
+$74.3M |
| 3 |
SentinelOne
S
|
+$45.9M |
| 4 |
DM
Desktop Metal, Inc.
DM
|
+$5.23M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 46.26% |
| 2 | Healthcare | 33.92% |
| 3 | Technology | 19.82% |
Similar funds
RC
ONGA
TC
PSFG
SCI
PVI
GBCP
IWM
DCVC Opportunity Fund II's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for DCVC Opportunity Fund II, which disclosed 4 positions worth $200M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Rocket Lab Corp: 7,203,035 shares worth $88.5M.
By sector, the portfolio is most concentrated in Industrials at 46% of assets, followed by Healthcare and Technology.
- DCVC Opportunity Fund II's largest Q4 2021 buy was Rocket Lab Corp: 7,203,035 shares worth $88.5M.
- DCVC Opportunity Fund II's ten largest holdings make up 100% of its $200M portfolio in Q4 2021.
- DCVC Opportunity Fund II disclosed 4 positions in Q4 2021, its first 13F filing on record.
Based on DCVC Opportunity Fund II's 13F filing for Q4 2021, filed 14 Feb 2022.